| 000 | 01632 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514072319.0 | ||
| 264 | 0 | _c20040211 | |
| 008 | 200402s 0 0 eng d | ||
| 022 | _a0041-1345 | ||
| 024 | 7 |
_a10.1016/s0041-1345(03)00379-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEmparan, C | |
| 245 | 0 | 0 |
_aCalcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function. _h[electronic resource] |
| 260 |
_bTransplantation proceedings _cJun 2003 |
||
| 300 |
_a1326-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aBasiliximab |
| 650 | 0 | 4 |
_aCalcineurin _xphysiology |
| 650 | 0 | 4 |
_aCreatinine _xblood |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aKidney Transplantation _ximmunology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycophenolic Acid _xanalogs & derivatives |
| 650 | 0 | 4 | _aRecombinant Fusion Proteins |
| 650 | 0 | 4 |
_aTissue Donors _xstatistics & numerical data |
| 700 | 1 | _aLaukötter, M | |
| 700 | 1 | _aWolters, H | |
| 700 | 1 | _aDame, C | |
| 700 | 1 | _aHeidenreich, S | |
| 700 | 1 | _aSenninger, N | |
| 773 | 0 |
_tTransplantation proceedings _gvol. 35 _gno. 4 _gp. 1326-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0041-1345(03)00379-8 _zAvailable from publisher's website |
| 999 |
_c12609189 _d12609189 |
||